Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Fish and Richardson
Chubb
McKesson
Deloitte
Covington
Citi
Dow
Cipla

Generated: August 15, 2018

DrugPatentWatch Database Preview

AURYXIA Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Auryxia patents expire, and when can generic versions of Auryxia launch?

Auryxia is a drug marketed by Keryx Biopharms and is included in one NDA. There are fourteen patents protecting this drug.

This drug has one hundred and eighteen patent family members in twenty-six countries.

The generic ingredient in AURYXIA is ferric citrate. There are seventeen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ferric citrate profile page.

Drug patent expirations by year for AURYXIA
Generic Entry Opportunity Date for AURYXIA
Generic Entry Date for AURYXIA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for AURYXIA
Synonyms for AURYXIA
1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron salt
1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron salt (1:?)
1,2,3-propanetricarboxylic acid, 2-hydroxy-, iron(2+) salt (2:3)
1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron(3+) salt
1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron(3+) salt (1:1)
11084-12-1
1185-57-5
12386-83-3
12549-57-4
17217-76-4 (trihydrate)
2-hydroxy-1,2,3-propanetricarboxylic acid iron salt
2-hydroxypropane-1,2,3-tricarboxylate; iron(3+)
23087-37-8
2338-05-8
2338-05-8 (unspecified iron salt)
28633-45-6
28633-45-6 (unspecified iron(+3) salt)
3522-50-7
3522-50-7 (Parent)
3B1-003934
47516-89-2
57979-58-5 (dihydrate)
6043-74-9
62709-48-2
63G354M39Z
7705-15-9
A832727
AC1L1UYI
ACM28633456
AKOS015918266
AN-19905
C6H5FeO7
CCRIS 6843
Citric acid iron(III) salt
Citric acid, iron salt
Citric acid, iron(3+) salt
Citric acid, iron(3+) salt (1:1)
CTK1C2869
D04CJL
DB09162
DTXSID0037657
EINECS 222-536-6
EINECS 249-117-0
Fe(III)-citrate complex (1:1)
FERRIC CITRATE
Ferric citrate (VAN)
Ferric citrate [USAN]
FERRICCITRATE
ferrum citricum
FT-0626407
FT-0627304
FT-0652224
H260
Hyperphosphatemia therapy, Panion/Keryx
I14-60931
I14-8077
Iron (III) citrate
Iron 2-hydroxy-1,2,3-propanetricarboxylate
Iron citrate
Iron citrate, FeC6H5O7
Iron, (hydrogen citrato(3-))-
iron(3+) citrate
iron(3+) ion 2-hydroxypropane-1,2,3-tricarboxylate
iron(3+); 2-oxidanylpropane-1,2,3-tricarboxylate
Iron(III) citrate
Iron(III) citrate tribasic
Iron(III)-citrate
JTT 751
JTT-751
KRX-0502
KS-0000108D
MCULE-2140052675
Nephoxil
NPFOYSMITVOQOS-UHFFFAOYSA-K
NSC 112227
OR020149
OR253005
PBF-1681
SCHEMBL42945
TR-037246
TRA0022730
UNII-63G354M39Z
Zerenex

US Patents and Regulatory Information for AURYXIA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Keryx Biopharms AURYXIA ferric citrate TABLET;ORAL 205874-001 Sep 5, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Keryx Biopharms AURYXIA ferric citrate TABLET;ORAL 205874-001 Sep 5, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Keryx Biopharms AURYXIA ferric citrate TABLET;ORAL 205874-001 Sep 5, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for AURYXIA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,913,821 Ferric organic compounds, uses thereof and methods of making same ➤ Try a Free Trial
9,750,715 Method of reversing, preventing, delaying or stabilizing soft tissue calcification ➤ Try a Free Trial
9,889,113 Method for reversing, preventing, delaying or stabilizing soft tissue calcification ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Chinese Patent Office
Fish and Richardson
Cerilliant
Medtronic
Argus Health
Chubb
US Army
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.